United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2016_register
executive
2016-04-19
article
Prospective Grant of Exclusive License: The Development of MRI-1569, MRI-2213 and MRI-2214 as a Therapeutic To Treat Obesity, Diabetes, Fatty Liver Disease and Liver Fibrosis
Notices
D09002ee1bdc1c988
D09002ee1bdc1c9f6
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
National Institutes of Health
originator
org
United States Government Agency or Subagency
This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the following inventions embodied in the following patent applications, entitled ``CB1 receptor mediating compounds'':
81 FR 22997
https://www.govinfo.gov/app/details/FR-2016-04-19/2016-08986
2016-08986
fr19ap16-54
4140-01-P
https://www.govinfo.gov/app/details/FR-2016-04-19/2016-08986
https://www.govinfo.gov/content/pkg/FR-2016-04-19/html/2016-08986.htm
https://www.govinfo.gov/content/pkg/FR-2016-04-19/pdf/2016-08986.pdf
2 p.
22997
22998
81 FR 22997
Prospective Grant of Exclusive License: The Development of MRI-1569, MRI-2213 and MRI-2214 as a Therapeutic To Treat Obesity, Diabetes, Fatty Liver Disease and Liver Fibrosis; Federal Register Vol. 81, Issue
NOTICE
2016-08986
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
2016-05-04
4140-01-P
2016-08986
Notice.
This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the following inventions embodied in the following patent applications, entitled ``CB1 receptor mediating compounds'':
Only written comments and/or applications for a license which are received by the Technology Advancement Office, The National Institute of Diabetes and Digestive and Kidney Diseases on or before May 4, 2016 will be considered.
Exclusive Licenses:
Development of MRI1569, MRI2213 and MRI2214 as a Therapeutic to Treat Obesity, Diabetes, Fatty Liver Disease, and Liver Fibrosis
,
betty.tong@nih.gov
Federal Register
Vol. 81, no. 75
Office of the Federal Register, National Archives and Records Administration
2016-04-19
continuing
daily
deposited
born digital
253 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2016-04-19
P0b002ee18f3aea1b
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr19ap16
https://www.govinfo.gov/app/details/FR-2016-04-19
https://www.govinfo.gov/content/pkg/FR-2016-04-19/pdf/FR-2016-04-19.pdf
https://www.govinfo.gov/content/pkg/FR-2016-04-19/xml/FR-2016-04-19.xml
fdlp
22911
23154
DGPO
2016-04-19
2023-04-29
FR-2016-04-19
machine generated
eng
FR
FR-2016-04-19
81
75